Online support platform for managing symptoms and side effects in metastatic sarcoma
Tests a personalized web platform supporting adults with advanced or metastatic sarcoma.
Plain-language title generated from the registry record
Registry title: Study of the Impact of Digital Health Interventions on Symptom & Side-Effect Management in Metastatic Sarcoma Patients
Key facts
- Where
- Athens and Thessaloniki, GreeceSee the 11 sites
Where in Greece
- 251 Air Force General HospitalAthens, GreeceTaking people
- 401 General Military HospitalAthens, GreeceTaking people
- Attikon Hospital, 2nd clinicAthens, GreeceTaking people
- Attikon Hospital, 4th clinicAthens, GreeceTaking people
- HYGEIA HospitalAthens, GreeceTaking people
- Ippokrateio General HospitalAthens, GreeceTaking people
- Metropolitan General HospitalAthens, GreeceTaking people
- Mitera HospitalAthens, GreeceTaking people
- BioclinicThessaloniki, GreeceTaking people
- Ippokratio General Hospital of ThessalonikiThessaloniki, GreeceTaking people
- Papageorgiou General HospitalThessaloniki, GreeceTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- CareAcross
- Trial code
- NCT07642375
- Record updated
- 11 June 2026
- Original description
The objective of this prospective study is to capture the quality of life of patients with locally advanced or metastatic sarcoma, and investigate the effectiveness of support provided through a personalized web-based platform.Read full original descriptionShow less
Observational, Randomized, Prospective Study of the Impact of Digital Health Interventions on Symptom and Side-Effect Management in Patients With Metastatic Sarcoma
The objective of this prospective study is to capture the quality of life of patients with locally advanced or metastatic sarcoma, and investigate the effectiveness of support provided through a personalized web-based platform.
Inclusion: Age of ≥ 18 years; Diagnosis of locally advanced or metastatic sarcoma of any location and origin; Ability to understand and operate in a digital environment; Patients planned to start standard of care treatment within the next month, or are currently undergoing standard of care treatment of any line; Treatments include surgery, radiotherapy, chemotherapy, immunotherapy, targeted therapy, hormonal therapy, or any combination of the above.
Exclusion: Participation in an interventional clinical trial with investigational drugs or devices; Limited ability or willingness to report side-effects on an online platform; Performance status >3; Life expectancy of <6 months.